Light Chain Deposition Disease
10
2
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
20%
2 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Registry for Adults With Plasma Cell Disorders (PCD's)
Rifaximin in Patients With Monoclonal Gammopathy
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy